Oscar Health, Inc. (OSCR)
Oscar Health, Inc. (OSCR) Surpasses Market Returns: Some Facts Worth Knowing
Oscar Health, Inc. (OSCR) closed at $15.35 in the latest trading session, marking a +2.88% move from the prior day.
Oscar Health, Inc. (OSCR) Stock Slides as Market Rises: Facts to Know Before You Trade
Oscar Health, Inc. (OSCR) closed at $15.53 in the latest trading session, marking a -3.42% move from the prior day.
Why Oscar Health, Inc. (OSCR) Dipped More Than Broader Market Today
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $16.55, marking a -1.55% move from the previous day.
Why I'm Buying Oscar's Panic Dip
Centene's $1.8B ACA risk shock triggered a ~15-20% drop in Oscar's stock but didn't alter Q1 fundamentals. Oscar posted 42% revenue growth, expanding to 2 million members with a record-low 15.8% SG&A expense ratio. Barclays' downgrade highlights policy risk, projecting over 100bps MLR pressure and aggressive EPS cuts if subsidies expire.
Oscar Health: Should You Buy OSCR Stock At $17?
On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified?
Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why
Oscar Health, Inc. (OSCR) concluded the recent trading session at $16.62, signifying a -18.73% move from its prior day's close.
Oscar Health, Inc. (OSCR) Declines More Than Market: Some Information for Investors
Oscar Health, Inc. (OSCR) closed the most recent trading day at $20.45, moving 4.62% from the previous trading session.
Oscar Health: A Misunderstood Platform
Oscar generated $328.8 million in Q1 adjusted EBITDA with a 9.8% operating margin, up 110 bps year-over-year. SG&A ratio fell to 15.8%, driven by 40% fixed-cost leverage and 15% tech-driven efficiencies like 98% auto-claims processing. A 5-year DCF with 30% FCF growth and a 5x terminal multiple supports a $61/share fair value, over 3x upside.
Oscar Health: Building The Operating System Of American Healthcare
Oscar Health's tech-driven flywheel is shrinking costs, boosting retention, and driving rapid membership growth, validated by 42% revenue growth and record profitability in Q1 2025. Platform revenue from +Oscar and data licensing is compounding faster than insurance premiums, creating a high-margin, SaaS-like earnings stream that legacy insurers can't match. Favorable policy trends and employer adoption of ICHRAs funnel incremental lives to Oscar at low acquisition cost, while Oscar's consumer-centric UX and provider partnerships deepen its moat.
Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $20.42, marking a -3.77% move from the previous day.
Still Cheap After Near 100% Gains? Oscar Health Stock Could Continue Higher
Oscar Health, Inc. is undervalued despite a recent rally, with strong growth and earnings potential as a tech-driven disruptor in health insurance. The company boasts accelerating revenues, improving profitability, a robust balance sheet, and positive cash flow, supporting further upside. ACA enrollment growth, favorable ICHRA trends, and industry disruption position Oscar for continued success and margin expansion.
Oscar Health: I'm Bullish, But I'm Careful
Oscar Health is uniquely undervalued, combining 42% revenue growth with profitability and a low EV/Sales multiple, making it a standout in the market. The company's $2.23B cash position versus its $4.8B market cap highlights significant balance sheet strength and downside protection. ICHRA market expansion offers massive upside potential, but regulatory risks and limited pricing power cap long-term sustainability.
